IGM Biosciences, Inc.
IGMS
$1.22
$0.032.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 412.00K | 516.00K | 1.25M | 497.00K | 651.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 412.00K | 516.00K | 1.25M | 497.00K | 651.00K |
| Cost of Revenue | 23.27M | 46.14M | 41.96M | 43.82M | 52.46M |
| Gross Profit | -22.86M | -45.63M | -40.71M | -43.32M | -51.81M |
| SG&A Expenses | 1.76M | 18.76M | 10.65M | 10.54M | 11.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.03M | 64.90M | 52.61M | 54.35M | 63.94M |
| Operating Income | -24.62M | -64.39M | -51.36M | -53.86M | -63.29M |
| Income Before Tax | -36.65M | -61.43M | -47.90M | -49.82M | -60.45M |
| Income Tax Expenses | -- | -- | -- | -- | 242.00K |
| Earnings from Continuing Operations | -36.65M | -61.43M | -47.90M | -49.82M | -60.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.65M | -61.43M | -47.90M | -49.82M | -60.70M |
| EBIT | -24.62M | -64.39M | -51.36M | -53.86M | -63.29M |
| EBITDA | -22.26M | -62.08M | -49.08M | -51.68M | -61.11M |
| EPS Basic | -0.60 | -1.01 | -0.79 | -0.83 | -1.01 |
| Normalized Basic EPS | -0.30 | -0.63 | -0.50 | -0.52 | -0.63 |
| EPS Diluted | -0.60 | -1.01 | -0.79 | -0.83 | -1.01 |
| Normalized Diluted EPS | -0.30 | -0.63 | -0.50 | -0.52 | -0.63 |
| Average Basic Shares Outstanding | 60.85M | 60.66M | 60.43M | 60.11M | 59.83M |
| Average Diluted Shares Outstanding | 60.85M | 60.66M | 60.43M | 60.11M | 59.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |